



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 31.12.2011

Particulars	Rs. in lacs				
	Quarter ended 31.12.2011 Unaudited	Quarter Ended 31.12.2010 Unaudited	9 Month ended 31.12.2011 Unaudited	9 Month Ended 31.12.2010 Unaudited	12 Months Ended 31.03.2011 Audited
1a Net sales/Income from Operations	4659.67	4209.39	13505.20	12909.97	16095.50
1b Other Operating Income					
Total	4659.67	4209.39	13505.20	12909.97	16095.50
2 Expenditure					
a. (Inc./Dec. in Stock in trade & work in progress	-859.90	39.31	-1411.43	835.80	192.46
b. Consumption of Raw Materials	2806.38	1925.61	7255.59	5052.13	7379.61
c. Purchase of traded goods	260.31	236.18	696.59	802.89	727.95
d. Employees Cost	966.89	886.38	2745.12	2472.57	3222.48
e. Depreciation	75.50	51.34	195.58	166.45	220.09
f. Other Expenditure	1009.28	860.33	2916.48	2447.93	3119.94
g. Total	4256.46	3999.15	12397.93	11777.77	14862.53
3 Profit from Operations before Other Income, Interest and Exceptional items (1-2)	401.21	210.24	1107.27	1132.20	1232.97
4 Other Income	19.34	0.00	25.35	0.00	26.02
5 Profit before interest and Exceptional items (3+4)	420.55	210.24	1132.62	1132.20	1258.99
6 Interest	103.09	95.13	282.74	281.46	332.18
7 Profit after Interest but before Exceptional Items (5-6)	317.46	115.11	849.88	850.74	926.81
8 Exceptional Items					
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	317.46	115.11	849.88	850.74	926.81
10 Tax expense	85.23	37.00	198.23	172.00	208.85
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	232.23	78.11	651.65	678.74	717.96
12 Extraordinary Items (net of tax expense)					
13 Net Profit(+)/Loss(-) for the period(11-12)	232.23	78.11	651.65	678.74	717.96
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of pr.					6615.03
16 Earnings Per Share (EPS)					
a. Basic & diluted EPS before extraordinary items for the period.	0.89	0.30	2.49	2.59	2.74
b. Basic & diluted EPS after extraordinary items for the period.	0.89	0.30	2.49	2.59	2.74
17 Public shareholding :					
- Number of shares	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding					
A Pledged / encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
B Non - encumbered					
- Number of shares	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%

Notes

- The Financial Results for the Quarter ended 31.12.2011 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 13-02-2012
- No complaints were pending at the beginning/end of the quarter ended 31.12.2011. However 40 requests for change of address/ dividend revaluation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

- 34 -

Place : New Delhi
Date : 13.02.2012

Certified True Copy
For Jagsonpal Pharmaceuticals Ltd.

Sunder
Company Secretary

Rajpal Singh Kochhar
Managing Director

**Limited Review Report
Jagsonpal Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 31.12.2011, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For P.P.Thukral & Co.
Chartered Accountants**

Place : New Delhi
Date: 13.02.2012



Suresh Sethi
**Suresh Sethi
Partner**

F.R.No. 000632N
Membership No. 89318